NEWS | alsv | Page 4 of 17

Companies in the News

Laronde banks $440M to ramp up RNA-based meds that could turn cells into protein factories

Laronde launched out of Flagship Labs this year with a lofty vision: to deliver as many as 100 new RNA medicines over the next 10 years....

Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases

Redefining neuroscience research and development with a data-driven precision neuroscience platform to develop targeted therapies for...

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company

Common stock and warrants expected to commence trading on Nasdaq on August 26, 2021 under the ticker symbols EFTR and EFTRW SAN DIEGO,...

BiotechBayer bets $1.5B that Vividion will help it target the 'undruggable' and make 1+1=3

Sometimes, it takes $1.5 billion to make "one plus one equal three." Bayer wanted to "really transform" its R&D engine under its recently...

Ring Therapeutics Raises $117 Million in Series B Funding to Expand Novel Vector Platform

Ring's novel vector Anellogy™ platform harnesses unique properties of anelloviruses to create a pipeline of redosable vectors compatible...

Pacific Biosciences Signs Definitive Agreement to Acquire Omniome

Combination aims to transform the genomics landscape and deliver a differentiated product offering into high growth clinical markets...

Vividion Therapeutics Files for IPO

Vividion Therapeutics Inc., a biotechnology company that seeks to develop drugs for cancer and immune disorders using "traditionally...

Tempest and Millendo Announce Stockholder Approval of Merger

Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST” SOUTH SAN FRANCISCO, Calif. and ANN ARBOR, Mich., June 22, 2021 (GLOBE...

Lyell Immunopharma Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming...